Design considerations for handling dropouts in anti-depressant drug trials

Our findings suggest that MDD trials in the acute setting may be shortened to 6 weeks provided that the treatment difference between drug and placebo on HAMD-17 total score reaches approximately 2 units at Week 6. However, our exploratory analyses of available data do not support the use of time to treatment discontinuation as an alternative primary efficacy endpoint.